Lemonaid Health
Lemonaid Health is a cash-pay telehealth platform founded in 2013 that offers GLP-1 medications for weight loss alongside primary care and mental health services. The company has had a turbulent ownership history: acquired by 23andMe for $400 million in 2021, then sold to Bambu Ventures for just $10 million in 2025 after 23andMe's Chapter 11 bankruptcy filing. The 97.5% value destruction raises legitimate questions about long-term platform stability.
Overview
- Consultation Model
- Async Telehealth
- Headquarters
- San Francisco, CA
- Shipping
- 3-5 business days
- Lab Testing
- Yes
- Prescriber Info
- Licensed healthcare providers evaluate patients and prescribe based on clinical eligibility.
- Founded
- 2013
Pros
- Broad medication menu: compounded and brand-name, semaglutide and tirzepatide
- Zepbound vial integration via LillyDirect
- Annual lab testing included (most budget competitors skip this)
- Microdose options provide a lower-cost entry point
- Multi-month commitment discounts available
- No long-term contract required
Cons
- Expensive.
- No insurance accepted
- No coaching or behavioral support
- Ownership instability.
- $3.25M privacy settlement
- Not available in all 50 states
Pricing
| Medication | Dose | Price | Billing |
|---|---|---|---|
| tirzepatide | 2.5-15mg/week | $348 | monthly |
| semaglutide | 0.25-2.4mg/week | $348 | monthly |